Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10096-024-04844-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oritavancin a Therapeutic Option for Periprosthetic Joint Infections in Selected Cases: A Comprehensive Review.
Pharmaceuticals (Basel)
August 2025
Faculty of Medicine, Lucian Blaga University of Sibiu, 550169 Sibiu, Romania.
Periprosthetic joint infections (PJIs) remain among the most challenging complications in orthopedic surgery, often requiring prolonged antibiotic therapy and complex surgical interventions. Oritavancin, a long-acting semisynthetic lipoglycopeptide approved for acute bacterial skin and skin structure infections, has emerged as a potential off-label agent in PJI treatment due to its favorable pharmacokinetic properties, potent Gram-positive coverage, and documented antibiofilm activity. This comprehensive review aims to assess the current clinical and preclinical data regarding the potential use of oritavancin in the management of PJIs.
View Article and Find Full Text PDFOne-Shot, One Opportunity: Retrospective Observational Study on Long-Acting Antibiotics for SSTIs in the Emergency Room-A Real-Life Experience.
Pathogens
August 2025
Infectious Diseases Unit, ARNAS Civico-Di Cristina Hospital, 90100 Palermo, Italy.
Background: Skin and soft tissue infections (SSTIs) are a major cause of emergency room (ER) visits and hospitalizations. Long-acting lipoglycopeptides (LALs), such as dalbavancin and oritavancin, offer potential for early discharge and outpatient management, especially in patients at risk for methicillin-resistant (MRSA) or with comorbidities.
Methods: We conducted a retrospective observational cohort study from March to December 2024 in an Italian tertiary-care hospital.
Background: Dalbavancin and oritavancin are long-acting lipoglycopeptides frequently used off-label to avoid outpatient parenteral antimicrobial therapy or placement of a central line at hospital discharge for patients with infections. Although dalbavancin and oritavancin have higher acquisition costs compared with commonly used antibiotics, such as vancomycin and daptomycin, they may reduce overall cost of health care.
Methods: This single-center, retrospective, cost-minimization analysis compared treatment with oritavancin and dalbavancin vs vancomycin and daptomycin.
Long-acting lipoglycopeptides compared to standard-of-care for the treatment of complicated gram-positive infections: A systematic review and meta-analysis.
Int J Antimicrob Agents
July 2025
University of Missouri - Kansas City School of Pharmacy at MU, Columbia, MO, USA. Electronic address:
Objectives: Long-acting lipoglycopeptides (LA-LGPs) are being used more frequently for the treatment of complicated Gram-positive infections, including osteomyelitis, prosthetic joint infections, bloodstream infections, and endocarditis. This systematic review and meta-analysis compared the efficacy and safety of LA-LGP to the standard of care (SOC) antibiotics for the treatment of these infections.
Methods: A systematic literature search was conducted using PubMed, Medline, Embase, Cochrane, and Clinicaltrials.
Oritavancin for the Treatment of Bacteremia-A Retrospective Single-arm Cohort Study.
Open Forum Infect Dis
July 2025
Department of Infectious Diseases, John Hunter Hospital, Newcastle, Australia.
Introduction: Patients who require prolonged intravenous antibiotics for bacteremia (SAB) and who are ineligible for outpatient parental antibiotic therapy (OPAT) present a challenge in regard to delivering appropriate and cost-effective treatment. Oritavancin, a novel long-acting lipoglycopeptide, shows promise as an alternative to OPAT for patients with complex Gram-positive infections, including those with SAB.
Objectives: To assess the outcomes, including safety and impact on length of stay and cost-effectiveness of using oritavancin for patients with SAB who are ineligible for OPAT.